Abstract
21 patients with malignant germ cell tumours of the ovary were treated with two chemotherapy regimens including vinblastine, actinomycin-D, bleomycin, cyclophosphamide and cisplatin. Chemotherapy was delivered as primary postoperative therapy in 15 patients and for recurrent disease in 6 patients. 3 of 4 patients with pure dysgerminomas and 10 of 17 patients with non-dysgerminomatous tumours are alive without evidence of disease. The overall progression-free survival is 62% (95% confidence interval 45-77) with a median follow-up of 7 years. Two toxic deaths were observed. Less toxicity and better efficacy favour etoposide- and cisplatin-based regimens as standard chemotherapy for germ cell tumours of the ovary.
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / analysis
-
Bleomycin / administration & dosage
-
Cisplatin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Dactinomycin / administration & dosage
-
Female
-
Germinoma / chemistry
-
Germinoma / drug therapy*
-
Germinoma / surgery
-
Humans
-
Methotrexate / administration & dosage
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm, Residual
-
Ovarian Neoplasms / chemistry
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / surgery
-
Salvage Therapy
-
Vinblastine / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Biomarkers, Tumor
-
Bleomycin
-
Dactinomycin
-
Vincristine
-
Vinblastine
-
Cyclophosphamide
-
Cisplatin
-
Methotrexate